SCHEMBL1072471

SCHEMBL1072471

C=Cc1cc2ccc(OC)cc2nc1O[C@H]1CN(C(=O)OC(C)(C)C)[C@](C)(C(=O)O)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.36
KDM4E B2RXH2 3/20 0.36
NPC1 O15118 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
HPGDS O60760 6/20 0.34
PPARD Q03181 1/20 0.34
PPARA Q07869 1/20 0.34
BACE1 P56817 1/20 0.34
PIK3CD O00329 2/20 0.33
PIK3CA P42336 2/20 0.33
PIK3CB P42338 2/20 0.33
PIK3CG P48736 2/20 0.33
DYRK1A Q13627 1/20 0.32
ALDH1A1 P00352 2/20 0.32
HPGD P15428 2/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
SLC2A1 P11166 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1083353 1.00 RAB9A (0.36) RAB9AKDM4ENPC1L3MBTL1HPGDS
SCHEMBL1072580 0.89 RAB9A (0.36) RAB9AKDM4ENPC1L3MBTL1HPGDS
SCHEMBL21800693 0.84 BACE1 (0.34) RAB9AKDM4ENPC1L3MBTL1HPGDS
SCHEMBL3305756 0.84 SLC2A1 (0.33) RAB9AKDM4ENPC1L3MBTL1BACE1
SCHEMBL1583415 0.84 BACE1 (0.37) RAB9AKDM4ENPC1L3MBTL1HPGDS
SCHEMBL21800783 0.83 BACE1 (0.34) RAB9AKDM4ENPC1L3MBTL1HPGDS
SCHEMBL12934504 0.78 RAB9A (0.44) RAB9AKDM4ENPC1L3MBTL1PPARD
SCHEMBL2427449 0.77 PIK3CD (0.38) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL3302407 0.77 GPR119 (0.36) KDM4E
SCHEMBL1068681 0.77 KDM4E (0.36) RAB9AKDM4ENPC1L3MBTL1BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002884-A1 THERAPEUTIC COMPOUNDS MERCK SHARP & DOHME LLC 2011-01-06 US disclosed
US-20100099695-A1 HCV NS3 Protease Inhibitors MSD ITALIA S.R.L. (IT) 2010-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099695-A1 HCV NS3 Protease Inhibitors HAVCR2, GTF3C3, CTSC RAB9A 2463/4885KDM4E 2747/4885NPC1 172/4885
US-20110002884-A1 THERAPEUTIC COMPOUNDS RRP1B, ZC3HAV1, RNASE1 RAB9A 692/4885KDM4E 2417/4885NPC1 554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.